Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $CABA
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/20/2024 | $15.00 → $6.00 | Outperform → In-line | Evercore ISI |
12/19/2024 | $12.00 → $6.00 | Overweight → Equal Weight | Wells Fargo |
10/10/2024 | $10.00 | Buy | UBS |
2/5/2024 | $36.00 | Buy | Jefferies |
11/29/2023 | $38.00 | Outperform | William Blair |
10/24/2023 | $40.00 | Overweight | Cantor Fitzgerald |
10/19/2023 | $31.00 | Buy | Stifel |
9/5/2023 | $22.00 | Buy | Citigroup |
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform
Technology Adoption Program (TAP) program success demonstrates the ability of Cellares' IDMO Smart Factory to automate, lower costs and scale out manufacturing for Cabaletta Bio's clinical-stage CAR T program to treat patients with autoimmune diseases. Cellares, the first Integrated Development and Manufacturing Organization (IDMO), has concluded the Technology Adoption Program (TAP) on its automated cell therapy manufacturing Cell Shuttle™ for resecabtagene autoleucel, (rese-cel, previously known as CABA-201). Rese-cel is the lead clinical candidate in development by Cabaletta Bio, a biotechnology company focused on developing and launching the first curative targeted cell therapies desig
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:50 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the News and Events section of the Company's website at www.cabalettabio.com. Replays will be available on the website for 30 days. About Cabaletta BioCabaletta Bio (NASDAQ:CABA) is a clinical-stage b
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosuppressants and are off or tapering steroids as of the latest follow-up – – Safety profile continues to suggest favorable risk-benefit in the first 10 patients dosed; 90% of patients experienced either no CRS or Grade 1 CRS (fever) and 90% of patients experienced no ICANS – – Deep B cell depletion observed in all patients after rese-cel infusion with a transitional naïve B cell phenotype upon repopulation; tissue-resident
Cabaletta Bio downgraded by Evercore ISI with a new price target
Evercore ISI downgraded Cabaletta Bio from Outperform to In-line and set a new price target of $6.00 from $15.00 previously
Cabaletta Bio downgraded by Wells Fargo with a new price target
Wells Fargo downgraded Cabaletta Bio from Overweight to Equal Weight and set a new price target of $6.00 from $12.00 previously
UBS initiated coverage on Cabaletta Bio with a new price target
UBS initiated coverage of Cabaletta Bio with a rating of Buy and set a new price target of $10.00
SEC Form 4 filed by President, Science & Tech. Binder Gwendolyn
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
SEC Form 4 filed by Chief Financial Officer Marda Anup
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
SEC Form 4 filed by General Counsel Gerard Michael
4 - Cabaletta Bio, Inc. (0001759138) (Issuer)
Amendment: Cabaletta Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure
8-K/A - Cabaletta Bio, Inc. (0001759138) (Filer)
Cabaletta Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events
8-K - Cabaletta Bio, Inc. (0001759138) (Filer)
Cabaletta Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events
8-K - Cabaletta Bio, Inc. (0001759138) (Filer)
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello has over 35 years of experience in the life sciences industry, including specific expertise in CD19-CAR T therapy, where she most recently served as the Chief Commercial Officer of Kite Pharma, Inc. between 20
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru
Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel
PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel. "We are very pleased to welcome Mike to the executive team. His experience with a wide range of strategic legal and corporate matters within the life sciences industry will complement the management team as we advance clinical development for DSG3-CAART in our DesCAARTes™ trial, and further develop follow-on candidates from our deep pipeline of precision therapies for pati
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinical response – – All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion and through the follow-up period – – Consistent and complete B cell depletion observed in all patients within the first month after CABA-201 infusion; evidence of transitional naïve B cell repopula
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients – – Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 – – Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International – – Cash, cash
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion – – Improvements in both patients' specific disease measures, consistent with academic experience of a similar 4-1BB CD19-CAR T, suggest emerging clinical benefit with CABA-201 while discontinuing all disease-specific therapies other than a planned steroid taper in one patient – – Immature, naïve B cell repopulation in first IMNM patient observed at week 8 consistent with a potential immu
Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.
SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)
Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.
SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)
Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.
SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)